Company profile
Neumora Therapeutics, Inc.
NASDAQ:NMRABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Navacaprant | phase3 | — | 6 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04221230 | phase2 | completed | 2020-01-03 | 2022-04-08 | Neumora Therapeutics, Inc. | Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo |
| NCT06058013 | phase3 | completed | 2023-12-20 | 2026-05-06 | Neumora Therapeutics, Inc. | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
| NCT06058039 | phase3 | completed | 2023-12-21 | 2026-05-04 | Neumora Therapeutics, Inc. | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder |
| NCT06029439 | phase3 | active_not_recruiting | 2023-11-10 | 2027-06-01 | Neumora Therapeutics, Inc. | Study to Assess the Safety and Effectiveness of NMRA-335140-501 |
| NCT06546995 | phase1 | completed | 2024-07-09 | 2025-11-19 | Neumora Therapeutics, Inc. | Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease |
FDA applications (0)
No records yet.